TapImmune, Inc. today announced that the Company will host a conference call and live audio webcast on Wednesday, May 31, 2017, at 4:30 p.m. ET, to provide a corporate and clinical update for the first quarter 2017.
In honor of National Nurses week, TapImmune would like to recognize and say thank you for all the hard work and dedication you put in every time you put those scrubs on! Being a nurse can be rewarding and difficult. Without you, patients would be left in the dark. Thank you for being the light for your patients. We especially would like to recognize Oncology Nurses.
Targeting the immune system to fight cancer is not new: in 1891, New York bone sarcoma surgeon William B. Coley injected a patient with an inoperable malignant tumor with streptococcal organisms. His theory was that the resulting severe bacterial infection, erysipelas, would stimulate the immune system, shrinking the tumor.
On May 1st, TapImmune announced Richard Kenney, MD, FACP, was joining TapImmune to lead the Clinical Development Program. Dr. Kenney will manage TapImmune’s ongoing and planned clinical programs for its next-generation T-cell vaccine candidates, which currently include multiple Phase 2 trials in advanced breast and ovarian cancer.
TapImmune is advancing two Phase II studies that are funded by ~$17 million in non-dilutive grants from the U.S. Department of Defense.
Ovarian cancer is known as the most dangerous and serious gynecologic cancer. What’s even scarier is the women that are important in our lives are at risk of developing this disease. May 8, 2013, was the first World Ovarian Cancer Day. This day was created so that each year, individuals can raise awareness of this horrific disease that takes 140,000 women per year internationally.
AstraZeneca’s IMFINZI™ (Durvalumab) Receives US FDA Accelerated Approval For Previously Treated Patients With Advanced Bladder Cancer
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to IMFINZI™ (durvalumab). IMFINZI is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy, or whose disease has progressed within 12 months of receiving platinum-containing chemotherapy before (neoadjuvant) or after (adjuvant) surgery.
TapImmune announced that on May 1, 2017, Dr. Richard Kenney will manage TapImmune’s ongoing and planned clinical programs for its next-generation T-cell vaccine candidates, which currently include multiple Phase 2 trials in advanced breast and ovarian cancer.
TapImmune Inc. announced that on April 28,2017, Dr. John Bonfiglio resigned as Chief Operating Officer, President and director of TapImmune Inc. to pursue other opportunities.